



## **Press Release**

**For Immediate Distribution**

### **HO WAH GENTING BERHAD GROUP Q3 SALES SURGED BY 103.5%**

---

**KUALA LUMPUR, 26 November 2020 – Ho Wah Genting Berhad (“HWGB” or the “Company”)** (Bursa Stock Code:9601), announced its financial results for the third quarter ended 30 September 2020 (“Q3 2020”) today, HWGB Group’s revenue grew by 103.5% to RM96.1 million for the Q3 2020 compared with RM47.2 million in the preceding year’s corresponding quarter amid the unprecedented uncertainties arising from the Covid-19 pandemic outbreak.

For the cumulative nine months ended 30 September 2020, HWGB Group’s total revenue stood at RM197.5 million, representing a rise of 34.7% vis-à-vis RM146.6 million in preceding year corresponding nine months ended 30 September 2019. The higher revenue achieved for the financial period ended 30 September 2020 was mainly due to higher demand from existing customers of USD46.5 million as compared to USD34.6 million in the manufacturing division. The weakening of RM against the USD also contributed to the higher revenue which is denominated in RM.

In line with the substantial increase in revenue, net profit from manufacturing division for the nine months stood higher at RM5.5 million compared to RM4.3 million in preceding year corresponding period.

Nonetheless, on the Group level, HWGB recorded a net loss of RM1.5 million. This was mainly attributable to initial operating expenses incurred for the newly setup healthcare division pursuant to the recent diversification into healthcare business which include expenses on application(s) for necessary license(s) and/ or approval(s) for Covid-19 related medical devices and pharmaceuticals, purchasing of medical devices and staff costs incurred for the recruitment of professionals.

Commenting on the HWGB Group’s steadfast performance, HWGB Chief Executive Officer, Dato’ Aaron Lim noted: "Despite the commendable financial results from our core business unit, the management will continue to adopt prudent approach to manage the unpredictable uncertainties arising from the global Covid-19 pandemic." "We hope that the diversification will help to turnaround the Group and well position ourselves for the upcoming 2021 financial year which bodes well with our plans in rolling out Covid-19 related medical devices under the pipelines", Dato’ Aaron Lim further added.

“Our diversification into the healthcare-related business gives us a firm foundation for plans to roll out COVID-19-related medical devices while we have also invested in the research and development of vaccine for the prevention of COVID-19. We see a successful vaccine as bringing in sustainable long-term revenue for the Company”. “The race to produce a COVID-19 vaccine through conducting Phase IV clinical trial based on the poliomyelitis virus vaccine is well on the way through our joint venture partner, E-MO Biology Inc (“**EBI**”), which last month obtained approval from the United States Food and Drug Administration for the Phase IV clinical trial. As soon as the Phase IV clinical trial is proven effective, we will start mass producing the vaccine”.

Please refer to the US Food and Drug Administration website below for more information on EBI’s Phase IV clinical study.

<https://www.clinicaltrials.gov/ct2/show/NCT04639375>

\*\*\*

---

#### **ABOUT HO WAH GENTING BERHAD**

**Ho Wah Genting Berhad** (“**HWGB**” or the “**Company**”) is principally engaged in investment holdings and the provision of management services to its subsidiaries. The Company had on 30 June 2020 diversified its existing businesses to include healthcare related industry which mainly involved in health supplement, biotechnology and health technology. In addition, the Company and its subsidiaries (“**HWGB Group**” or the “**Group**”) are also engaging in the businesses of investment holdings; manufacturing of wires and cables and moulded power supply cord sets and cable assemblies for electrical and electronic devices and equipment; trading of wires and cables; and travel agent and tour related services.

For more information about healthcare and biotechnology products, please follow us on <https://hwgbbiotech.com>, <http://subscription.hwgbbiotech.com>, [Facebook](#), [LinkedIn](#) and [Telegram](#) to view the latest updates about our company ventures in the healthcare industry.



新闻稿  
供即时发布

## 豪华云顶第三季度销售额飙涨 103.5%

（吉隆坡，2020年11月26日）豪华云顶有限公司（Ho Wah Genting Berhad, **HWGB**）（大马交易所股票代码：**9601**）今天公布其截至2020年9月30日止的第三季度（“**Q3 2020**”）财务业绩。在新型冠状病毒（COVID-19）爆发带来的空前不确定性下，豪华云顶集团2020第三季度的销售额增长了103.5%至9610万令吉，比较去年同期是4720万令吉。

截至2020年9月30日止的首9个月，豪华云顶集团的总营业额为1亿9750万令吉，相较截至2019年9月30日为止首9个月的1亿4660万令吉增长了34.7%。截至2020年9月30日财政期间营业额增加主要归功于来自印尼制造部门的现有客户需求增长从3457万令吉至4647万令吉。此外，令吉兑美元走软也为以令吉计价的收入增长作出贡献。

与收入大幅增长相符，相较2019年制造部门的净利润在这九个月里为550万令吉，高于去年同期的430万令吉。

无论如何，豪华云顶集团财报显示150万令吉的净亏损。这主要是因为集团最近多元化业务至医疗保健领域，设立新的医疗保健业务产生的初始运营费用所致，主要包括与新型冠状病毒相关的医疗器械和药品的必要许可申请和/或批准费用，医疗器械的购买以及招募专业人员所产生的员工费用。

豪华云顶总执行长拿督林伟雄在评论集团的稳健业绩时指出：“尽管我们核心业务的业绩取得了值得赞许之际，管理层仍将继续采取谨慎措施来管理全球新型冠状病毒带来那不可预测的不确定性。”他补充：“我们希望多元化将有助于扭转集团的局面，并为即将到来的2021财年做好准备，这对我们在推出新冠肺炎相关医疗设备的计划来说是个好兆头。”

“我们将业务触角延伸至医疗保健相关业务的多元化计划，为我们推出与新型冠状病毒相关的医疗设备奠定了坚实的基础；同时我们也已投资于预防新型冠状病毒之疫苗的研发。我们认为疫苗的成功将为公司带来可持续的长期收入。在生产新型冠状病毒疫苗的竞赛我们通过合作伙伴 E-MO Biology Inc（“EBI”）

进行脊髓灰质炎病毒疫苗的第四期临床试验，。于上个月已获得美国食品和药物监督管理局的批准进行第四期临床试验。一旦第四期临床试验证明有效，我们将开始批量生产有关疫苗。”

有关 EBI 第四期临床试验的更多信息，请参阅美国食品和药物监督管理局的官方网站。

<https://www.clinicaltrials.gov/ct2/show/NCT04639375>

\*\*\*

---

#### 关于豪华云顶有限公司

**豪华云顶有限公司**（“HWGB”或“公司”）是一家投资控股公司，主要向其子公司提供管理服务。公司于 2020 年 6 月 30 日将其现有业务多元化，至涵盖医疗保健相关行业，主要包括健康补充剂，生物技术和医疗技术。此外，其公司及其子公司（“HWGB 集团”或“集团”）也涉及投资控股业务；电子电器设备的电线和电缆以及模压电源线组和电缆组件的制造；电线和电缆贸易；以及旅行社和旅游相关服务。

欲知更多有关豪华云顶生物科技的信息，请通过以下管道追踪我们，<https://hwgbbiotech.com>,  
<http://subscription.hwgbbiotech.com>, [Facebook](#), [LinkedIn](#) 和 [Telegram](#)，以获知有关我们公司在医疗保健领域的最新更新。